An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
For remission induction and maintenance therapy of acute lymphatic leukemia.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.